			EP 89100038	A	19890103		
ES 2059565	T3	19941116	EP 89100038	A	19890103	C12N-015/39	199501
IE 63619	B	19950517	IE 8963	A	19890111	A61K-039/285	199527
JP 2589797	B2	19970312	JP 893875	A	19890112	C12N-007/00	199715

Priority Applications (No Type Date): CH 8885 A 19880112
Cited Patents: 1.Jnl.Ref; EP 110385; EP 198328; EP 261940; EP 83286; CH 568392
Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
EP 324350	A	G	13			
US 5185146	A		8			
EP 324350	B1	G	13			
DE 58906121	G			Based on		EP 324350
ES 2059565	T3			Based on		EP 324350
JP 2589797	B2		9	Previous Publ.		JP 2005860

Abstract (Basic): EP 324350 A

A modified vaccinia cirus, Ankara strain (MVA) contg a DNA sequence which encodes for a foreign antigen (Ag) is disclosed. Also disclosed are vaccines contg this recombinant MVA.

MVA has been deposted as CNCM I-721 and can be grown in chicken embryo cells. Foreign DNA, also including a non-essential segment of vaccinia DNA, is introduced into infected cells, eg by Ca phosphate pptn or electroporation foreign DNA is partic a plasmid, esp pHGS-2/5.1 (see EP 198328) which contains the gene for the 5.1 antigen of Plasmodium falciparum. The DNA must contain suitable regulators, eg the vaccinia 11k or 7.5k gene promoters. Recombination between foreign and viral DNA occurs and recombinants selected, esp for absence of a functional thymidine kinase gene.

USE/ADVANTAGE - The vaccines are useful for preventing infections caused by pathogens corresponding to Ag, and recombinant MVA can also be used to express heterologous protein in eucaryotic cells. MVA is strongly attenuated, eg 10 million lower neurovirulence than the wild type strain WR.

Dwg.0/0

Abstract (Equivalent): EP 324350 B

A method for the preparation of a recombinant MVA caccinia virus, characterised by (a) infecting eukaryotic cells with the MVA vaccinia virus, (b) introducing into the infected cells a DNA which contains, within a partial sequence from a non-essential segment of the vaccinia virus DNA, a DNA sequence which codes for a foreign antigen and (c) isolating the recombinant MVA vaccinia virus in a manner known per se.

Dwg. 0/0

Abstract (Equivalent): US 5185146 A

Modified vaccinia virus Ankara useful in vaccine formulations comprises a DNA sequence encoding a foreign antigen without impairing the viability of the MVA. Foreign antigen is pref. a malaria parasite Plasmodium falciparum.

USE/ADVANTAGE - Prophylaxis of Plasmodium falcipanem infections. (Dwg.0/0)

Title Terms: MODIFIED; VACCINIA; VIRUS; STRAIN; CONTAIN; FOREIGN; DNA; ENCODE; ANTIGEN; USEFUL; PROTECT; VACCINE; HETEROLOGOUS; PROTEIN; EXPRESS
Derwent Class: B04; D16
International Patent Class (Main): A61K-039/12; A61K-039/285; C12N-007/00; C12N-015/39
International Patent Class (Additional): A61K-039/275; A61K-039/28; C12N-005/16; C12N-007/01; C12N-015/00; C12P-021/02
File Segment: CPI
Manual Codes (CPI/A-N): B02-V02; B04-B02B4; B04-B04A1; D05-H03B; D05-H07; D05-H12
Chemical Fragment Codes (M1):